Revolutionizing Gene Editing: Northwestern Researchers Develop Highly Efficient CRISPR Delivery System with DNA Nanotechnology
For decades, the promise of gene editing has captivated the medical world. CRISPR-Cas9 technology, a revolutionary tool for precise genome modification, holds the potential to cure genetic diseases, develop novel cancer therapies, and fundamentally reshape healthcare. However, a meaningful hurdle has remained: effectively and safely delivering CRISPR machinery into cells to achieve therapeutic impact. Now,a team led by renowned nanoscientist Chad Mirkin at Northwestern University has unveiled a groundbreaking solution – a novel delivery system leveraging spherical nucleic acid (SNA) technology that dramatically enhances CRISPR’s efficacy and broadens its therapeutic potential.
The Challenge of CRISPR Delivery: A Critical bottleneck
CRISPR’s power lies in its ability to precisely target and modify DNA within cells. This allows for gene disruption, mutation correction, and even the introduction of new functionalities. However, CRISPR isn’t a self-sufficient system. It requires a “delivery vehicle” to traverse the cellular barriers and reach its target.
Currently, two primary methods dominate the field: viral vectors and lipid nanoparticles (LNPs).While viruses are highly efficient at entering cells, their use is often hampered by the risk of triggering an immune response, possibly leading to adverse side effects. LNPs, while safer, suffer from low efficiency, frequently becoming trapped within cellular compartments (endosomes) before releasing their valuable CRISPR cargo.As Mirkin explains, “Only a fraction of the CRISPR machinery actually makes it into the cell and even a smaller fraction makes it all the way into the nucleus.” Alternative approaches, like ex vivo gene editing (removing cells, modifying them, and re-introducing them), are impractical for widespread clinical application.
Introducing LNP-SNAs: A DNA-Wrapped Taxi for CRISPR
Mirkin, a professor of Chemical and Biological Engineering, Biomedical Engineering, Materials Science and Engineering at Northwestern’s McCormick School of Engineering, and a professor of Medicine at the Feinberg School of medicine, has dedicated his career to pioneering innovative nanotechnology solutions. His team’s breakthrough centers around SNAs – globular structures of DNA and RNA previously developed in his lab. These structures, roughly 50 nanometers in diameter, are uniquely designed to encapsulate a nanoparticle core loaded with therapeutic cargo.
The new system, dubbed LNP-SNAs, begins with a standard LNP carrying the CRISPR machinery. This LNP is then decorated with a dense layer of short DNA strands. this seemingly simple modification unlocks a cascade of benefits:
Enhanced Cellular Uptake: The DNA coating facilitates interaction with cell surface receptors, dramatically increasing the rate at which cells absorb the LNP-SNAs.
Targeted Delivery: The DNA strands can be engineered with specific sequences to target particular cell types, enabling precision medicine approaches.
Rapid Internalization: “The SNA architecture is recognized by almost all cell types, so cells actively take up the SNAs and rapidly internalize them,” Mirkin notes. This bypasses the endosomal entrapment issues plaguing traditional LNP delivery.
Demonstrated Success Across Multiple Cell Types
The efficacy of LNP-SNAs was rigorously tested in vitro using a diverse range of human cells, including skin cells, white blood cells, human bone marrow stem cells, and human kidney cells. The results were compelling. The system consistently demonstrated:
High Internalization Efficiency: LNP-SNAs were readily absorbed by cells.
Low Toxicity: The system exhibited minimal toxicity to the tested cell lines. Accomplished Gene Delivery: CRISPR machinery was effectively delivered to the cells.
Precise Gene Editing: Analysis confirmed that CRISPR successfully made the desired genetic modifications.
These findings represent a significant leap forward in CRISPR delivery technology.
From Bench to Bedside: Clinical Translation and Future Directions
Mirkin’s team is now focused on validating the LNP-SNA system in in vivo* disease models, paving the way for clinical translation.The modular nature of the platform allows for adaptation to a wide range of therapeutic applications. Notably, Northwestern spin-out flashpoint Therapeutics, already conducting Phase 2 clinical trials for Merkel cell carcinoma using SNA-based therapies, is actively commercializing the technology to accelerate its journey to patients.
“CRISPR could change the whole field of medicine,” Mirkin emphasizes. “but how we design the delivery vehicle is just as vital as the genetic tools themselves. By marrying two powerful biotechnologies – CRISPR and SNAs – we have created a strategy that could unlock CRISPR’s full therapeutic potential.”
This research, supported by the Air Force Office of Scientific Research (FA9550-22-1-0300) and the National Science Foundation (DMR-2428112), alongside funding